Radioimmunoassay Market Size to Exceed $1.93 Billion by 2035

The global Radioimmunoassay Market is valued at USD 1.20 billion in 2025 and is projected to reach USD 1.93 billion by 2035, growing at a CAGR of 4.89% over the forecast period 2026–2035. As per the SNS Insider report titled, “Radioimmunoassay Market Size, Share & Segmentation Analysis, by Product Type, Radioisotope, Application, End User & Region | Global Forecast 2026–2035”.

Radioimmunoassay (RIA) is an in vitro, and highly sensitive method which is still being utilized for hormone detection due to its high degree of accuracy and reliability. Despite the development of non-radioactive alternatives, including ELISA, which has been available in recent years, radioimmunoassay (RIA) is still regarded as an appropriate procedure for identifying the presence of various substances in biological fluids because of its unique sensitivity.

Rising Demand for High-Sensitivity Diagnostic Techniques Driving Market Growth

Increasing prevalence of hormone related diseases, cancer biomarkers and rising infections globally are one of the major driving factors for the demand for radioimmunoassay technology. Clinical statistics suggest the prevalence of endocrine disorders to be greater than 10% worldwide and requires accurate diagnosis spurring the growth for radioimmunoassay technology in testing.

Additionally, a growing adoption of radioimmunoassay for pharmacokinetics and drug analysis is adding to its volume of applications. Pharmaceutical companies use radioimmunoassy to study the metabolism of the drugs and bioavailability due to its high sensitivity.

However, the requirement for strict regulations on radioactive substances, the high cost of disposal and the availability of alternative, safer options like chemiluminescence immunoassay (CLIA) are hindering large-scale application in routine clinical tests.

Key Report Highlights

Based on product type. Reagents & Kits have 44.8% market share followed by Software segment with 7.9% CAGR growth rate.
By type, Iodine-125 accounted for the largest share (41.2%) of the radioisotopes market due to its ideal half-life, high efficiency properties, while Indium-111 is anticipated to grow with the highest CAGR of 8.1%.
On the basis of applications, Endocrinology held the largest market share of 46.5%, owing to the growing use of hormone testing. The CAGR was 7.6% for Drug Testing & Pharmacokinetics applications,
By End Users: Among the three sub-segments, Clinical Laboratories had the biggest market with 42.7% of blood collection tubes in the global market, while the Pharmaceutical & Biotechnology Companies with a CAGR of 7.4% was the strongest growing market.
North America led with a share of 36.0%, and the fastest growing region was Asia Pacific, with a CAGR of 6.73%.

Regional Outlook

In 2025, North America led the Radioimmunoassay Market, with a share of 36.0% due to high penetration for advanced diagnostic facilities, large investment in healthcare, and the presence of key players. The country held a revenue share of USD 0.30 Billion in the year 2025 and is projected to grow at the rate of 4.62% CAGR over the analysis period, reaching USD 0.47 Billion by the end of 2035.

Europe has a stable nuclear diagnostic industry, even without reaching endemic use of radioligand therapy, since clinical research methodologies are well structured and regulated. The European nations such as Germany and France are continuously looking to invest in clinical laboratory automation technology.

The Asia Pacific is the most lucrative region for green building in terms of high growth potential with a CAGR of 6.73% during 2026 to 2035. This is facilitated mainly by the rapidly growing healthcare infrastructures along with the rising awareness of diagnostic technologies in the Chinese and Indian biotechnology industries.

Recent Industry Developments

2024: The portfolio of Revvity, Inc. was enhanced in the field of immunodiagnostics by developing radiometric assay technologies for use in clinical research.
2025: Siemens Healthineers AG developed its nuclear medicine diagnostics division by integrating advanced imaging compatible assay technologies.
2024: Danaher Corporation (Beckman Coulter) improved its immunoassays platform to enhance workflow efficiency and analysis accuracy.
2025: DiaSorin S.p.A. concentrated on specialty immunodiagnosis, which included the development of specialty assay techniques for RIA workflows.

Leading Companies in the Radioimmunoassay Market